Photobiomodulation for Cognitive Dysfunction (Brain Fog) in Post-COVID-19 Condition: A Randomized Sham-Controlled Pilot Trial
Lim, L.; Hosseinkhah, N.; Buskirk, M. V.; Oei, K.; Berk, A.; Pushparaj, A.; Liburd, J.; Abbaspour, Z.; Rubine, J.; Jackson, D.; Zomorrodi, R.
Show abstract
Post-COVID-19 condition (PCC) affects millions globally, with cognitive dysfunction ("brain fog") impairing daily functioning in up to 88% of patients. No effective treatments exist for PCC-related cognitive impairment. We conducted a randomized, double-blind, sham-controlled pilot clinical trial to evaluate the efficacy of home-based photobiomodulation (PBM) using the Vielight Neuro RX Gamma device in 43 adults with PCC. Participants received 8 weeks of daily 20-minute PBM or sham treatment, targeting the default mode network. The primary outcome was change in cognitive performance (Creyos battery) at Day 56. Active PBM showed greater improvement in composite cognitive scores (p=0.088), with significant gains in participants under 45 years (p=0.028). Attention tasks improved consistently across groups. PBM was safe, with high compliance and no serious adverse events. These findings suggest PBMs potential as a non-invasive intervention for PCC cognitive impairment, warranting larger trials to confirm efficacy.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Reversal of Biological Age in Multiple Rat Organs by Young Porcine Plasma Fraction 91%
- Restoration of Gamma Center Frequency via Personalized Entrainment Marks Cognitive Preservation in Early Alzheimer's Disease 91%
- The RESIST Senior Individuals Cohort: Design, participant characteristics and aims 90%
Similar papers in this journal
- Dementia Risk and Machine Learning-Derived Brain Age Index from Sleep Electroencephalography: A Pooled Cohort Analysis of Over 7,000 Individuals Across Five Community Cohorts 90%
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis 90%
- Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial 89%
Similar papers in this journal
- Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam) 93%
- Randomized Clinical Trial of ICECaP (Individualized Coordination and Empowerment for Care Partners of Persons with Dementia): Primary Mental Health and Burden Outcomes 93%
- The Healthy Brain Initiative (HBI): A prospective cohort study protocol 93%
Similar papers in this journal
- A Remote Digital Memory Composite to Detect Cognitive Impairment in Memory Clinic Samples in Unsupervised Settings using Mobile Devices 93%
- Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network to Simulate Clinical Trials of Alzheimer’s Disease 92%
- The Physiologic Response to COVID-19 Vaccination 92%
Similar papers in this journal
- An Interpretable Machine Learning Tool for In-Home Screening of Agitation Episodes in People Living with Dementia 91%
- Remote Digital Cognitive Assessment Reveals Cognitive Deficits Related to Hippocampal Atrophy in Autoimmune Limbic Encephalitis 90%
- Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.